These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32593280)

  • 21. Tailoring Lipid and Polymeric Nanoparticles as siRNA Carriers towards the Blood-Brain Barrier - from Targeting to Safe Administration.
    Gomes MJ; Fernandes C; Martins S; Borges F; Sarmento B
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):107-119. PubMed ID: 27209050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanobiotechnology-based drug delivery in brain targeting.
    Dinda SC; Pattnaik G
    Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Insight in Improving Therapeutic Efficacy of Antipsychotic Agents: An Overview of Improved In Vitro and In Vivo Performance, Efficacy Upgradation and Future Prospects.
    Ei Thu H; Hussain Z; Shuid AN
    Curr Drug Targets; 2018; 19(8):865-876. PubMed ID: 27894237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral bioavailability: issues and solutions via nanoformulations.
    Pathak K; Raghuvanshi S
    Clin Pharmacokinet; 2015 Apr; 54(4):325-57. PubMed ID: 25666353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route.
    Patel S; Chavhan S; Soni H; Babbar AK; Mathur R; Mishra AK; Sawant K
    J Drug Target; 2011 Jul; 19(6):468-74. PubMed ID: 20958095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative assessment of efficacy and safety potential of multifarious lipid based Tacrolimus loaded nanoformulations.
    Jain S; Addan R; Kushwah V; Harde H; Mahajan RR
    Int J Pharm; 2019 May; 562():96-104. PubMed ID: 30902706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid nanoparticles as vehicles for oral delivery of insulin and insulin analogs: preliminary ex vivo and in vivo studies.
    Muntoni E; Marini E; Ahmadi N; Milla P; Ghè C; Bargoni A; Capucchio MT; Biasibetti E; Battaglia L
    Acta Diabetol; 2019 Dec; 56(12):1283-1292. PubMed ID: 31407113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier.
    Dal Magro R; Ornaghi F; Cambianica I; Beretta S; Re F; Musicanti C; Rigolio R; Donzelli E; Canta A; Ballarini E; Cavaletti G; Gasco P; Sancini G
    J Control Release; 2017 Mar; 249():103-110. PubMed ID: 28153761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects.
    Joseph E; Reddi S; Rinwa V; Balwani G; Saha R
    Eur J Pharm Sci; 2017 Jun; 104():315-325. PubMed ID: 28408348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent Advances in Delivery of Peptide and Protein Therapeutics to the Brain.
    Arora S; Bajaj T; Kumar J; Goyal M; Singh A; Singh C
    J Pharmacol Exp Ther; 2024 Jan; 388(1):54-66. PubMed ID: 37977811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoparticulate-based drug delivery systems for small molecule anti-diabetic drugs: An emerging paradigm for effective therapy.
    Uppal S; Italiya KS; Chitkara D; Mittal A
    Acta Biomater; 2018 Nov; 81():20-42. PubMed ID: 30268916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical Drug Delivery of Anti-infectives Employing Lipid-Based Nanocarriers: Dermatokinetics as an Important Tool.
    Thakur K; Sharma G; Singh B; Katare OP
    Curr Pharm Des; 2018; 24(43):5108-5128. PubMed ID: 30657036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Vitro and Ex Vivo Evaluations of Lipid Anti-Cancer Nanoformulations: Insights and Assessment of Bioavailability Enhancement.
    Jain AS; Dhawan VV; Sarmento B; Nagarsenker MS
    AAPS PharmSciTech; 2016 Jun; 17(3):553-71. PubMed ID: 27068527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of solid lipid nanoparticles for sustained drug release.
    Attama AA; Umeyor CE
    Ther Deliv; 2015; 6(6):669-84. PubMed ID: 26149784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal delivery of antipsychotic drugs.
    Katare YK; Piazza JE; Bhandari J; Daya RP; Akilan K; Simpson MJ; Hoare T; Mishra RK
    Schizophr Res; 2017 Jun; 184():2-13. PubMed ID: 27913162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid Nanoparticles: A Novel Approach for Brain Targeting.
    Shankar R; Joshi M; Pathak K
    Pharm Nanotechnol; 2018; 6(2):81-93. PubMed ID: 29886842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanoneurotherapeutics approach intended for direct nose to brain delivery.
    Md S; Mustafa G; Baboota S; Ali J
    Drug Dev Ind Pharm; 2015; 41(12):1922-34. PubMed ID: 26057769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Delivery to the Brain across the Blood-Brain Barrier Using Nanomaterials.
    Tsou YH; Zhang XQ; Zhu H; Syed S; Xu X
    Small; 2017 Nov; 13(43):. PubMed ID: 29045030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ethyl oleate-containing nanostructured lipid carriers improve oral bioavailability of trans-ferulic acid ascompared with conventional solid lipid nanoparticles.
    Zhang Y; Li Z; Zhang K; Yang G; Wang Z; Zhao J; Hu R; Feng N
    Int J Pharm; 2016 Sep; 511(1):57-64. PubMed ID: 27374194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art.
    Gastaldi L; Battaglia L; Peira E; Chirio D; Muntoni E; Solazzi I; Gallarate M; Dosio F
    Eur J Pharm Biopharm; 2014 Aug; 87(3):433-44. PubMed ID: 24833004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.